Supplemental Digital Content 1 – Systematic Literature Review

Supplemental Digital Content 1 – Systematic Literature Review

ProQuest strategy

Table 1 – Search terms for MEDLINE (via ProQuest)

Topic Set# Searched for

Wet AMD S1 MESH.EXACT(“Macular Degeneration”) OR “macular degeneration”

S2 MESH.EXACT(“choroidal neovascularization”) OR “choroidal neovascularization” OR “choroidal neovascularisation”

S3 (wet OR exudative) AND (S1 OR S2)

S4 MESH.EXACT(“wet macular degeneration”) OR “wet degeneration”

OR “macular disease”

S5 “wet age-related macular disease” OR “wet age-related macular degeneration” OR “AMD” OR “ARMD”

S6 Exudative AND (“age-related macular degeneration” OR “AMD” OR

“ARMD”)

S7 Neovascular AND (“age-related macular degeneration” OR “AMD”

OR “ARMD”)

S8 “age-related maculopathy”

S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 Aflibercept S10 aflibercept OR Eylea

Wet AMD & Aflibercept S11 S9 AND S10 AMD, age-related macular degeneration

Inclusion and exclusion criteria according to the PICOS criteria

Inclusion criteria Exclusion criteria Population  Wet AMD

 Treatment-naïve patients

 Studies with mixed ophthalmology indications will only be included if results for wet AMD patients are reported separately

 Studies with mixed treatment-naïve and previously treated patients will be included if results for treatment-naïve patients are reported separately

 Non-humans

 Specific subtypes of wet AMD (e.g.

RAP, PCV)

 Other ophthalmology indications

 No separately reported results for wet AMD population

 Patients that switch treatments while in the study and do not report the minimum 2-year data while in treatment with aflibercept

 Previously treated patients (treatment-experienced patients)

 No separately reported results for treatment-naïve patients

Interventions  Aflibercept (Eylea^®) monotherapy  Other interventions besides aflibercept

Comparators  Comparator effectiveness studies will not be excluded.

 NA Outcomes  At 2 years (±6 weeks)

 Study needs to at least report on change in BCVA versus baseline, or BCVA at separate timepoints and baseline BCVA and number of injections

 Relevant endpoints at other timepoints (e.g. BCVA at 1 year and at 3 years – to be flagged only)

 Other timepoints and endpoints

Study design  Prospective study design (prospective data collection) or retrospective study design

 Non-intervention/observational study

 Interventional study (anti-VEGF treatment/regimen is not described by study protocol)

 Pragmatic trials

 RWE studies

 At least 40 patients

 Randomized studies

 Interventional study (the study prescribes a treatment regimen for patients, e.g. through protocol)

 Non-RWE studies

 Trials (except pragmatic trials)

 Systematic reviews, meta-analysis

 Editorials, newsletter

Language  English (full-text or abstracts)  Other languages

AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; NA, not applicable; PCV, polypoidal choroidal vasculopathy; PICOS, Population, Intervention, Comparison, Outcomes and Study; RAP, retinal angiomatous proliferation; RWE, real-world evidence; VEGF, vascular endothelial growth factor receptor 2